366 632

Cited 12 times in

Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: a multi-center analysis

DC Field Value Language
dc.contributor.author구교철-
dc.contributor.author김도경-
dc.contributor.author김종원-
dc.contributor.author나군호-
dc.contributor.author이광석-
dc.contributor.author이종수-
dc.contributor.author정병하-
dc.contributor.author하윤수-
dc.contributor.author한경석-
dc.contributor.author홍성준-
dc.date.accessioned2018-08-28T17:13:24Z-
dc.date.available2018-08-28T17:13:24Z-
dc.date.issued2018-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/162381-
dc.description.abstractBACKGROUND: Clinical trial (CT) participation may confer access to new, potentially active agents before their general availability. This study aimed to investigate the potential survival benefit of participation in investigational CTs of novel hormonal, chemotherapeutic, and radiopharmaceutical agents in patients with castration-resistant prostate cancer (CRPC). METHODS: This multi-center, retrospective analysis included 299 consecutive patients with newly diagnosed, non-metastatic or metastatic CRPC between September 2009 and March 2017. Of these, 65 (21.7%) patients participated in CTs pertaining to systemic treatment targeting CRPC and 234 (78.3%) patients received pre-established, standard systemic treatment outside of a CT setting. The survival advantage of CT participation regarding cancer-specific survival (CSS) was investigated. RESULTS: An Eastern Cooperative Oncology Group performance status (ECOG PS) >/=2 at CRPC diagnosis was found in a lower proportion CT participants than in non-participants (4.6% vs. 14.9%; p = 0.033). During the median follow-up period of 16.0 months, CT participants exhibited significantly higher 2-year CSS survival rates (61.3% vs. 42.4%; p = 0.003) than did non-participants. Multivariate analysis identified prostate-specific antigen and alkaline phosphatase levels at CRPC onset, Gleason score >/= 8, ECOG PS >/=2, less number of docetaxel cycles administered, and non-participation in CTs as independent predictors for a lower risk of CSS. CONCLUSIONS: Patients diagnosed with CRPC who participated in CTs exhibited longer CSS durations than non-participants who received pre-established, standard systemic therapy outside of a CT setting. Our findings imply that CT participation is associated with CSS, and that CT participation should be offered to patients with CRPC whenever indicated.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherBioMed Central-
dc.relation.isPartOfBMC CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleImpact of clinical trial participation on survival in patients with castration-resistant prostate cancer: a multi-center analysis-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Urology-
dc.contributor.googleauthorKyo Chul Koo-
dc.contributor.googleauthorJong Soo Lee-
dc.contributor.googleauthorJong Won Kim-
dc.contributor.googleauthorKyung Suk Han-
dc.contributor.googleauthorKwang Suk Lee-
dc.contributor.googleauthorDo Kyung Kim-
dc.contributor.googleauthorYoon Soo Ha-
dc.contributor.googleauthorKoon Ho Rha-
dc.contributor.googleauthorSung Joon Hong-
dc.contributor.googleauthorByung Ha Chung-
dc.identifier.doi10.1186/s12885-018-4390-x-
dc.contributor.localIdA00188-
dc.contributor.localIdA05453-
dc.contributor.localIdA04731-
dc.contributor.localIdA01227-
dc.contributor.localIdA02668-
dc.contributor.localIdA05500-
dc.contributor.localIdA03607-
dc.contributor.localIdA05526-
dc.contributor.localIdA04264-
dc.contributor.localIdA04402-
dc.relation.journalcodeJ00351-
dc.identifier.eissn1471-2407-
dc.identifier.pmid29695228-
dc.subject.keywordCastration-resistant-
dc.subject.keywordClinical trial-
dc.subject.keywordProstatic neoplasms-
dc.subject.keywordSurvival-
dc.contributor.alternativeNameKoo, Kyo Chul-
dc.contributor.alternativeNameKim, Do Kyung-
dc.contributor.alternativeNameKim, Jong Won-
dc.contributor.alternativeNameRha, Koon Ho-
dc.contributor.alternativeNameLee, Kwang Suk-
dc.contributor.alternativeNameLee, Jong Soo-
dc.contributor.alternativeNameChung, Byung Ha-
dc.contributor.alternativeNameHa, Yoon Soo-
dc.contributor.alternativeNameHan, Kyung Seok-
dc.contributor.alternativeNameHong, Sung Joon-
dc.contributor.affiliatedAuthorKoo, Kyo Chul-
dc.contributor.affiliatedAuthorKim, Do Kyung-
dc.contributor.affiliatedAuthorKim, Jong Won-
dc.contributor.affiliatedAuthorRha, Koon Ho-
dc.contributor.affiliatedAuthorLee, Kwang Suk-
dc.contributor.affiliatedAuthorLee, Jong Soo-
dc.contributor.affiliatedAuthorChung, Byung Ha-
dc.contributor.affiliatedAuthorHa, Yoon Soo-
dc.contributor.affiliatedAuthorHan, Kyung Seok-
dc.contributor.affiliatedAuthorHong, Sung Joon-
dc.citation.volume18-
dc.citation.number1-
dc.citation.startPage468-
dc.identifier.bibliographicCitationBMC CANCER, Vol.18(1) : 468, 2018-
dc.identifier.rimsid59965-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.